Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-07-30
2010-10-05
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S326000, C530S327000
Reexamination Certificate
active
07807171
ABSTRACT:
The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.The invention relates to said composition for defining means for treating multidrug resistances.
REFERENCES:
patent: 2006/0233758 (2006-10-01), Tosi et al.
patent: 2007/0281006 (2007-12-01), Nicolau et al.
patent: WO 94/10198 (1994-05-01), None
patent: WO 94/10198 (1994-05-01), None
patent: WO 9410198 (1994-05-01), None
Tosi et al. (Biochemical and Biophysical Research Communications 1995; 212: 494-500).
Bashir et al. (Virshows Arch. 1998; 432: 279-287).
Candido, K. A. et al, “Local Administration of Dendritic Cells Inhibits Established Breast Tumor Growth: Implications for Apoptosis-inducing Agents”, Cancer Research 61, Jan. 1, 2001, pp. 228-236.
Chen, C-J. et al, “Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells”, Cell 47(3), Nov. 7, 1986 pp. 381-389.
Deprez, B. et al, “Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL”, Vaccine, 1996, pp. 375-382, vol. 14, No. 5, Elsevier Science Ltd., Great Britain.
Endicott, J. A. et al, “The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance”, Annu. Rev. Biochem. 58, 1989, pp. 137-171, Annual Reviews Inc.
Fries, L.F. et al, “Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy”, Proc. Natl. Acad. Sci. USA, vol. 89, Jan. 1992, pp. 358-362.
Juliano, R. L. et al, “A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants”, Biochimica et Biophysica Acta 455, 1976, pp. 152-162, Elsevier/North-Holland Biomedical Press.
Klohs, W.D.et al, <<Resistance to Anthrapyrazoles and Anthracyclines in Multidrug-resistant P388 Murine Leukemia Cells : Reversal by Calcium Blockers and Calmodulin Antagonists >>, Cancer Research 46, Sep. 1986, pp. 4352-4356.
Mechetner, E.B. et al, ,,Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody, Proc. Natl. Acad. Sci. USA, vol. 89, Jul. 1992, pp. 5824-5828.
Miller, T. P. et al, “P-Glycoprotein Expression in Malignant Lymphoma and Reversal of Clinical Drug Resistance With Chemotherapy Plus High-Dose Verapamil”, Journal of Clinical Oncology, vol. 9, No. 1, Jan. 1991, pp. 17-24.
Pierré, A. et al, “In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative”, Investigational New Drugs 10, 1992, pp. 137-148, Kluwer Academic Publishers, Netherlands.
Roberts, M.J. et al, “Chemistry for peptide and protein PEGylation”, Advanced Drug Delivery Reviews 54, 2002, pp. 459-476, Elsevier Science B.V.
Schnolzer, M. et al, “Constructing Proteins by Dovetailing Unprotected Synthetic Peptides: Backbone-Engineered HIV Protease”, Science, New Series, vol. 256, No. 5054, Apr. 10, 1992, pp. 221-225, American Association for the Advancement of Science.
Stöber, P. et al, “Synthesis of Characteristic Lipopeptides of the HumanN-RasProtein and their Evaluation as Possible Inhibitors of Protein Farnesyl Transferase”, Bioorganic & Medicinal Chemistry, vol. 5, No. 1, 1997, pp. 75-83, Elsevier Science Ltd., Great Britain.
Stupp, R. et al, “Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial”, Annals of Oncology 9, 1998, pp. 1233-1242, Kluwer Academic Publishers, Netherlands.
Thiebault, F. et al, “Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues”, Proc. Natl. Acad. Sci. USA, vol. 84, Nov. 1987, pp. 7735-7738.
Tosi, P. et al, “Immune Response Against the Murine MDRI Protein Induced by Vaccination With Synthetic Lipopeptides in Liposomes”, Biochemical and Biophysical Research Communications, vol. 212, No. 2, Jul. 17, 1995, pp. 494-500, Academic Press, Inc.
Tsuruo, T., “6. Circumvention of drug resistance with calcium channel blockers and monoclonal antibodies”, inDrug Resistance in Cancer Therapy, 1989, p. 73-95, Ozols, R.F. (ed), Kluwer Academic Publishers.
Van Der Bliek, A.M. et al, “Sequence ofmdr3cDNA encoding a human P-glycoprotein”, Gene 71, 1988, pp. 401-411, Elsevier Science Publishers B.V. (Biomedical Division).
Yang, J. et al, “Treatment of Multidrug Resistant (MDR1) Murine Leukemia with P-Glycoprotein Substrates Accelerates the Course of the Disease”, Biochemical and Biophysical Research Communications 266, 1999, pp. 167-173, Academic Press.
U.S. Appl. No. 11/550,778, Tosi et al. unpublished.
Hickman David T.
Madoulet Claudie
Nicolau Claude
Tosi Pierre-Francois
AC Immune SA
Fetterolf Brandon J
Natzmer Joyce von
Pequignot & Myers LLC
LandOfFree
Therapeutic vaccine targeted against P-glycoprotein 170 for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic vaccine targeted against P-glycoprotein 170 for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic vaccine targeted against P-glycoprotein 170 for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234694